Table 5.
The probability of adverse outcomes occurrence and the types of outcomes in the four study groups.
| Variables | Status | The Study group |
p | |||||
|---|---|---|---|---|---|---|---|---|
| Fib. –F | Fib. +F | Inv. –F | Inv. +F | Total | ||||
| Major cardiac outcomes | Without adverse outcomes | Number | 39 | 47 | 57 | 46 | 189 | .07 |
| % | 32.5% | 44.3% | 48.7% | 41.8% | 41.7% | |||
| With adverse outcomes | Number | 81 | 59 | 60 | 64 | 264 | ||
| % | 67.5% | 55.7% | 51.3% | 58.2% | 58.3% | |||
| Total | Number | 120 | 106 | 117 | 110 | 453 | ||
| % | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |||
| Major cardiac outcomes | Without adverse outcomes | Number | 39 | 47 | 57 | 46 | 189 | .023 |
| % | 32.5% | 44.3% | 48.7% | 41.8% | 41.7% | |||
| Death | Number | 10 | 4 | 7 | 8 | 29 | ||
| % | 8.3% | 3.8% | 6.0% | 7.3% | 6.4% | |||
| Readmission | Number | 16 | 20 | 23 | 27 | 86 | ||
| % | 13.3% | 18.9% | 19.7% | 24.5% | 19.0% | |||
| Reintervention | Number | 55 | 35 | 30 | 29 | 149 | ||
| % | 45.8% | 33.0% | 25.6% | 26.4% | 32.9% | |||
| Total | Number | 120 | 106 | 117 | 110 | 453 | ||
| % | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |||
(Fib. +F), patients received fibrinolytic therapy with f-QRS; (Fib. –F), patients received fibrinolytic therapy without f-QRS; (Inv. +F), patients received invasive therapy with f-QRS; (Inv. –F), patients received invasive therapy without f-QRS.